tiprankstipranks
Trending News
More News >
Draegerwerk AG & Co. KGaA (0MT8) (DE:DRW8)
:DRW8
Advertisement

Draegerwerk AG & Co. KGaA (DRW8) AI Stock Analysis

Compare
1 Followers

Top Page

DE:DRW8

Draegerwerk AG & Co. KGaA

(LSE:DRW8)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
€67.00
▲(13.18% Upside)
Draegerwerk AG & Co. KGaA's stock score is driven by strong earnings call results and attractive valuation, indicating potential for future growth. Technical analysis supports a positive trend, although financial performance shows areas needing improvement. The company's ability to navigate economic challenges and enhance operational efficiency will be crucial for sustaining momentum.

Draegerwerk AG & Co. KGaA (DRW8) vs. iShares MSCI Germany ETF (EWG)

Draegerwerk AG & Co. KGaA Business Overview & Revenue Model

Company DescriptionDrägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as fire training facilities for firefighters. Drägerwerk AG & Co. KGaA was founded in 1889 and is headquartered in Lübeck, Germany.
How the Company Makes MoneyDraegerwerk generates revenue through the sale of its medical and safety technology products and services. Key revenue streams include the sale of medical devices, such as ventilators and monitoring systems, which are critical for healthcare providers, especially during emergencies or surgeries. Additionally, the company earns income from safety technology products, including personal protective equipment and gas detection systems for industrial applications. Draeger also offers maintenance and support services for its products, providing recurring revenue. Significant partnerships with hospitals and healthcare institutions, along with compliance with regulatory standards, further bolster its revenue. The company also invests in research and development to innovate and expand its product offerings, which helps maintain its competitive edge and drive sales.

Draegerwerk AG & Co. KGaA Earnings Call Summary

Earnings Call Date:Oct 29, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 24, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong order intake and sales growth, significant improvements in EBIT and share prices, and positive future outlooks. However, these achievements were tempered by challenges such as currency and tariff headwinds, weaker performance in China, and increased functional expenses.
Q3-2025 Updates
Positive Updates
Strong Order Intake and Sales Growth
Order intake rose by 9% to around EUR 2.6 billion in the first 9 months of 2025, driven by strong demand in the Americas with a 19% increase. Net sales increased by roughly 4% to around EUR 2.3 billion in the first 9 months.
Significant EBIT and Share Price Increase
EBIT more than doubled in Q3 to around EUR 57 million, with an EBIT margin increase from 3.6% to 6.8%. Preferred shares increased by around 63% year-to-date.
Improved Operating Cash Flow
Operating cash flow increased by more than EUR 35 million to around EUR 93 million in the first 9 months, indicating strong working capital management.
Positive Outlook for 2025
Net sales growth and EBIT margin are expected in the upper half of the forecast range, with net sales growth of 3.0% to 5.0% and an EBIT margin of 4.5% to 6.5%.
Negative Updates
Currency and Tariff Headwinds
Currencies and tariffs had a substantial negative impact on earnings, with FX having a negative impact of roughly EUR 22 million on EBIT.
Weak Business in China
Demand cooled considerably in China in Q3, resulting in a decline in net sales compared to the prior year quarter despite earlier growth in APAC.
Functional Expense Increase
Functional expenses increased around 6% in the first 9 months, mainly driven by the absence of last year's EUR 30 million one-off income.
Company Guidance
In the Q3 2025 Earnings Conference Call, Drägerwerk AG & Co. KGaA reported significant financial metrics, reflecting strong business performance despite economic challenges. Order intake rose by 9% to approximately EUR 2.6 billion, while net sales climbed over 10% in Q3, reaching EUR 2.3 billion for the first nine months. The EBIT for Q3 more than doubled to around EUR 57 million, with a margin increase from 3.6% to 6.8%. Operating cash flow improved substantially by over EUR 35 million, totaling approximately EUR 93 million. The company revised its net sales growth and EBIT margin expectations to the upper half of their forecast range, projecting net sales growth of 3.0% to 5.0% and an EBIT margin of 4.5% to 6.5% for the year. Despite facing currency and tariff headwinds, Dräger's strong order book and sales momentum underpin their optimistic outlook for the remainder of 2025.

Draegerwerk AG & Co. KGaA Financial Statement Overview

Summary
Draegerwerk AG & Co. KGaA shows a mixed financial performance. The balance sheet is strong with low leverage and a solid equity base. However, the income statement and cash flow metrics reveal challenges with declining revenue growth and cash generation. The company needs to improve operational efficiency and sales to enhance profitability.
Income Statement
65
Positive
Draegerwerk AG & Co. KGaA's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) gross profit margin is healthy at approximately 44.97%, indicating efficient cost management. However, the net profit margin has decreased to 3.42%, and the revenue growth rate is negative at -13.9%, signaling a decline in sales. EBIT and EBITDA margins have also contracted, reflecting operational challenges. The company needs to address these issues to improve profitability and growth.
Balance Sheet
70
Positive
The balance sheet of Draegerwerk AG & Co. KGaA is relatively stable. The debt-to-equity ratio is low at 0.26, indicating conservative leverage. Return on equity (ROE) is modest at 7.89%, suggesting moderate profitability for shareholders. The equity ratio stands at 49.03%, showing a strong equity base relative to total assets. Overall, the company maintains a solid financial position with manageable debt levels.
Cash Flow
55
Neutral
Cash flow analysis reveals some concerns. The free cash flow growth rate is negative, indicating a decline in cash generated from operations. The operating cash flow to net income ratio is low at 0.17, suggesting limited cash conversion efficiency. However, the free cash flow to net income ratio is relatively healthy at 0.62, showing some ability to generate cash relative to profits. The company needs to enhance its cash flow generation to support future investments and operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.36B3.37B3.37B3.05B3.33B3.41B
Gross Profit1.51B1.51B1.46B1.24B1.54B1.61B
EBITDA315.73M351.68M318.33M62.63M374.43M399.92M
Net Income99.86M124.41M110.43M-64.56M154.23M188.59M
Balance Sheet
Total Assets2.99B3.09B3.09B3.11B3.18B3.31B
Cash, Cash Equivalents and Short-Term Investments218.91M248.18M279.36M319.50M577.38M650.56M
Total Debt446.92M395.58M471.38M361.95M348.01M370.75M
Total Liabilities1.52B1.56B1.69B1.79B1.92B2.27B
Stockholders Equity1.46B1.54B1.41B1.32B1.26B1.03B
Cash Flow
Free Cash Flow122.22M103.52M121.47M-231.09M274.54M345.04M
Operating Cash Flow190.64M167.31M189.68M-144.23M384.89M459.98M
Investing Cash Flow-92.53M-43.39M-67.34M36.83M-109.92M-263.08M
Financing Cash Flow-103.70M-161.38M-154.56M-29.38M-334.64M114.25M

Draegerwerk AG & Co. KGaA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price59.20
Price Trends
50DMA
56.46
Positive
100DMA
56.45
Positive
200DMA
53.36
Positive
Market Momentum
MACD
1.27
Positive
RSI
55.52
Neutral
STOCH
75.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW8, the sentiment is Positive. The current price of 59.2 is below the 20-day moving average (MA) of 60.28, above the 50-day MA of 56.46, and above the 200-day MA of 53.36, indicating a bullish trend. The MACD of 1.27 indicates Positive momentum. The RSI at 55.52 is Neutral, neither overbought nor oversold. The STOCH value of 75.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DRW8.

Draegerwerk AG & Co. KGaA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
€46.61B21.8711.46%2.25%4.53%10.32%
73
Outperform
€1.23B9.558.22%3.20%2.14%6.69%
66
Neutral
€3.83B24.177.48%1.33%5.21%-39.36%
60
Neutral
€1.25B67.352.87%0.21%1.16%-43.53%
60
Neutral
€11.96B18.405.41%3.48%2.10%9.19%
60
Neutral
€270.47M16.882.97%-1.64%22.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:DRW8
Draegerwerk AG & Co. KGaA
61.60
21.60
53.98%
DE:AFX
Carl Zeiss Meditec
45.00
-12.22
-21.36%
DE:COP
CompuGroup Medical
24.00
9.05
60.56%
DE:FME
Fresenius Medical Care AG & Co. KGaA
41.40
-0.42
-1.00%
DE:SBS
STRATEC Biomedical
20.85
-6.23
-23.00%
DE:SHL
Siemens Healthineers AG
42.18
-7.58
-15.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 05, 2025